CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 99 enrolled
Drug / intervention
Aripiprazole +1 moredrug
Likely dose
Aripiprazole 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01292057
NCT01292057Phase 3Completed
CompareCT.gov

Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication

Medical University of South Carolina·interventional·Posted Feb 9, 2011·Updated Aug 8, 2017

In Brief

A Phase 3 clinical trial evaluating Aripiprazole and Placebo for Alcohol Dependence. Completed, enrolled 99 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving and drinking compared to placebo depending on participant's baseline level of impulsivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 9, 2011
Enrollment StartFeb 1, 2011
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 15.4 years ago

Interventions

Aripiprazoledrug

Aripiprazole(up to 15 mg/day) for 8 days

Placebodrug

Placebo to match active drug Aripiprazole for 8 days